Latest news with #RobbinsLLP
Malaysian Reserve
16 hours ago
- Business
- Malaysian Reserve
Investor Alert: Robbins LLP Informs Investors of the KinderCare Learning Companies, Inc. Class Action Lawsuit
SAN DIEGO, Aug. 13, 2025 /PRNewswire/ — Robbins LLP informs stockholders that a class action was filed on behalf of purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to the Company's October 2024 initial public offering ('IPO'). KinderCare provides early education and child care services in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that KinderCare Learning Companies, Inc. (KLC) Included Misleading Statements in its Registration Statement in Support of its IPO According to the complaint, defendants negligently prepared the Registration Statement in support of the IPO. Specifically, defendants failed to disclose: (a) that numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (b) that KinderCare did not provide the 'highest quality care possible' at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (c) that, as a result of (a)-(b) above, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss. What Now: You may be eligible to participate in the class action against KinderCare Larning Companies, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by October 14, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against KinderCare Learning Companies, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit
SAN DIEGO, Aug. 12, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Replimune Group, Inc. (REPL) Misled Investors Regarding the Viability of its IGNYTE Trial According to the complaint, during the class period defendants failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Plaintiff alleges that on July 22, 2025, Replimune announced that it had received a complete response letter ('CRL') from the FDA for RPI Biologics License Application for the treatment of advanced melanoma and that the CRL 'indicates that the FDA is unable to approve the application in its present form because the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. On this news, the price of Replimune stock plummeted by $9.52 per share, or 77.24%, to close at $2.80 per share on July 22, 2025. What Now: You may be eligible to participate in the class action against Replimune Group, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by September 22, 2025. Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Replimune Group, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
Sable Offshore Corp. Stockholders with Large Losses Should Contact Robbins LLP for Information About the SOC Class Action Lawsuit
SAN DIEGO, Aug. 12, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025 and June 3, 2025 and/or traceable to the Company's May 21, 2025 secondary public offering ('SPO'). Sable Offshore operates in the offshore drilling business and seeks to extract oil from the Santa Ynez field in federal waters off the coast of California. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Sable Offshore Corp. (SOC) Misled Investors Regarding Oil Production According to the complaint, during the class period, defendants represented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not. The complaint alleges that when the true details were revealed, investors suffered damage. What Now: You may be eligible to participate in the class action against Sable Offshore Corp. Shareholders who want to serve as lead plaintiff for the class must submit their papers with the court by September 26, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Flywire Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Business Upturn
07-08-2025
- Business
- Business Upturn
Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) — Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability of its IMPACT Phase 2b MASH Trial According to the complaint, during the class period, defendants repeatedly touted their positive expectations of the topline results of the Company's MASH trial. On June 26, 2025, Altimmune announced the results from its IMPACT Phase 2b MASH trial of Pemvidutide in the treatment of MASH. Specifically, the Company failed to achieve statistical significance in the trial due to a higher-than-expected placebo response. On this news, the price of Altimmune's common stock fell from $7.71 per share on June 25, 2025 to $3.61 per share on June 26, 25, or more than 53% in a single day. What Now: You may be eligible to participate in the class action against Altimmune, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their papers with the court by October 6, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Altimmune, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Malaysian Reserve
11-07-2025
- Business
- Malaysian Reserve
BRBR Investors Who Have Suffered Financial Losses Should Contact Robbins LLP About Their Investigation into the Officers and Directors of BellRing Brands, Inc.
SAN DIEGO, July 10, 2025 /PRNewswire/ — Shareholder rights law firm Robbins LLP is investigating BellRing Brands, Inc. (NYSE: BRBR) to determine whether certain BellRings Brands officers and directors violated securities laws and breached fiduciary duties to shareholders. BellRings Brands manufactures and sells nutrition products in the U.S. and internationally. What Now: If you own shares of BellRing Brands, Inc. and have lost money in your investment, contact us for more information about your rights. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Contact us to learn more: Aaron Dumas, Jr. (800) 350-6003adumas@ Shareholder Information Form About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against BellRing Brands, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
